发布求助
文献互助 智能选刊 最新文献

InFo Hämatologie + Onkologie最新文献

筛选
英文 中文
CD38-Antikörper auch beim rezidivierten Myelom CD38 抗体也可用于复发骨髓瘤
InFo Hämatologie + Onkologie Pub Date : 2024-05-01 DOI: 10.1007/s15004-024-0592-3
Redaktion Facharztmagazine
{"title":"CD38-Antikörper auch beim rezidivierten Myelom","authors":"Redaktion Facharztmagazine","doi":"10.1007/s15004-024-0592-3","DOIUrl":"https://doi.org/10.1007/s15004-024-0592-3","url":null,"abstract":"","PeriodicalId":503002,"journal":{"name":"InFo Hämatologie + Onkologie","volume":"22 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141058311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
„Der richtige Zeitpunkt, sich mit KI auseinanderzusetzen, ist jetzt!“ "现在就是掌握人工智能的最佳时机！"
InFo Hämatologie + Onkologie Pub Date : 2024-05-01 DOI: 10.1007/s15004-024-0566-5
Jakob Nikolas Kather
{"title":"„Der richtige Zeitpunkt, sich mit KI auseinanderzusetzen, ist jetzt!“","authors":"Jakob Nikolas Kather","doi":"10.1007/s15004-024-0566-5","DOIUrl":"https://doi.org/10.1007/s15004-024-0566-5","url":null,"abstract":"","PeriodicalId":503002,"journal":{"name":"InFo Hämatologie + Onkologie","volume":"6 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141056285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erster oraler SERD verbessert PFS gegenüber Standardtherapie 与标准疗法相比，首款口服 SERD 可改善 PFS
InFo Hämatologie + Onkologie Pub Date : 2024-05-01 DOI: 10.1007/s15004-024-0590-5
Martina Eimer
{"title":"Erster oraler SERD verbessert PFS gegenüber Standardtherapie","authors":"Martina Eimer","doi":"10.1007/s15004-024-0590-5","DOIUrl":"https://doi.org/10.1007/s15004-024-0590-5","url":null,"abstract":"","PeriodicalId":503002,"journal":{"name":"InFo Hämatologie + Onkologie","volume":"5 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141023636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kann Künstliche Intelligenz (KI) Entlassungsbriefe verständlicher machen? 人工智能（AI）能否让出院信更容易理解？
InFo Hämatologie + Onkologie Pub Date : 2024-05-01 DOI: 10.1007/s15004-024-0572-7
M. Borchers
{"title":"Kann Künstliche Intelligenz (KI) Entlassungsbriefe verständlicher machen?","authors":"M. Borchers","doi":"10.1007/s15004-024-0572-7","DOIUrl":"https://doi.org/10.1007/s15004-024-0572-7","url":null,"abstract":"","PeriodicalId":503002,"journal":{"name":"InFo Hämatologie + Onkologie","volume":"16 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141024474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HCC: Anhaltender Überlebensvorteil unter dem STRIDE-Regime HCC：采用 STRIDE 方案可持续获得生存获益
InFo Hämatologie + Onkologie Pub Date : 2024-05-01 DOI: 10.1007/s15004-024-0580-7
Silke Wedekind
{"title":"HCC: Anhaltender Überlebensvorteil unter dem STRIDE-Regime","authors":"Silke Wedekind","doi":"10.1007/s15004-024-0580-7","DOIUrl":"https://doi.org/10.1007/s15004-024-0580-7","url":null,"abstract":"","PeriodicalId":503002,"journal":{"name":"InFo Hämatologie + Onkologie","volume":"76 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141029121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunsuppression bei erworbener Hämophilie A ggf. hinauszögerbar 后天性血友病 A 的免疫抑制可能会延迟
InFo Hämatologie + Onkologie Pub Date : 2024-05-01 DOI: 10.1007/s15004-024-0573-6
M. Borchers
{"title":"Immunsuppression bei erworbener Hämophilie A ggf. hinauszögerbar","authors":"M. Borchers","doi":"10.1007/s15004-024-0573-6","DOIUrl":"https://doi.org/10.1007/s15004-024-0573-6","url":null,"abstract":"","PeriodicalId":503002,"journal":{"name":"InFo Hämatologie + Onkologie","volume":"35 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141039096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Auch Addition von CD38-Antikörper subkutan von Nutzen beim transplantierbaren Myelom 皮下注射 CD38 抗体对移植性骨髓瘤也有益处
InFo Hämatologie + Onkologie Pub Date : 2024-05-01 DOI: 10.1007/s15004-024-0578-1
Andreas Schalhorn
{"title":"Auch Addition von CD38-Antikörper subkutan von Nutzen beim transplantierbaren Myelom","authors":"Andreas Schalhorn","doi":"10.1007/s15004-024-0578-1","DOIUrl":"https://doi.org/10.1007/s15004-024-0578-1","url":null,"abstract":"","PeriodicalId":503002,"journal":{"name":"InFo Hämatologie + Onkologie","volume":"21 3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141025436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hoffnung, aber kein Durchbruch 希望，但没有突破
InFo Hämatologie + Onkologie Pub Date : 2024-05-01 DOI: 10.1007/s15004-024-0571-8
Robert Bublak
{"title":"Hoffnung, aber kein Durchbruch","authors":"Robert Bublak","doi":"10.1007/s15004-024-0571-8","DOIUrl":"https://doi.org/10.1007/s15004-024-0571-8","url":null,"abstract":"","PeriodicalId":503002,"journal":{"name":"InFo Hämatologie + Onkologie","volume":"21 S3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141046787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AML: PT-Cy als GvHD-Prophylaxe punktet bei nicht verwandten Spendern 急性髓细胞性白血病：PT-Cy 作为 GvHD 预防疗法为非亲属捐献者加分
InFo Hämatologie + Onkologie Pub Date : 2024-05-01 DOI: 10.1007/s15004-024-0594-1
Miriam Sonnet
{"title":"AML: PT-Cy als GvHD-Prophylaxe punktet bei nicht verwandten Spendern","authors":"Miriam Sonnet","doi":"10.1007/s15004-024-0594-1","DOIUrl":"https://doi.org/10.1007/s15004-024-0594-1","url":null,"abstract":"","PeriodicalId":503002,"journal":{"name":"InFo Hämatologie + Onkologie","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141047792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stabiles PI-RADS 3 benötigt wohl zunächst keine Folgebiopsie 稳定的 PI-RADS 3 可能最初不需要进行随访活检
InFo Hämatologie + Onkologie Pub Date : 2024-05-01 DOI: 10.1007/s15004-024-0602-5
Robert Bublak
{"title":"Stabiles PI-RADS 3 benötigt wohl zunächst keine Folgebiopsie","authors":"Robert Bublak","doi":"10.1007/s15004-024-0602-5","DOIUrl":"https://doi.org/10.1007/s15004-024-0602-5","url":null,"abstract":"","PeriodicalId":503002,"journal":{"name":"InFo Hämatologie + Onkologie","volume":"69 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141038689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信